Skip to main content

Table 3 Number (and rate) of specific harm reduction interventions identified in provincial and territorial policy documents

From: Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks

Case (no. of documents within cases) Harm reduction (unspecified) Needle/syringe distribution Naloxone Supervised injection or consumption Low-threshold opioid agonist treatment Buprenorphine/naloxone (Suboxone) Drug checking Safer inhalation kits
British Columbia (10) 208 (20.8) 31 (3.1) 6 (0.6) 22 (2.2) 0 (0.0) 1 (0.1) 0 (0.0) 3 (0.3)
Alberta (4) 78 (19.5) 9 (2.3) 0 (0.0) 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Saskatchewan (3) 253 (84.3) 109 (36.3) 0 (0.0) 38 (12.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3)
Manitoba (7) 80 (11.4) 13 (1.9) 1 (0.1) 2 (0.3) 0 (0.0) 0 (0.0) 1 (0.1) 2 (0.3)
Ontario (7) 9 (1.3) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Quebec (11) 42 (3.8) 11 (1.0) 0 (0.0) 17 (1.5) 5 (0.5) 0 (0.0) 1 (0.1) 0 (0.0)
New Brunswick (1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nova Scotia (4) 63 (15.8) 38 (9.5) 2 (0.5) 0 (0.0) 1 (0.3) 27 (6.8) 0 (0.0) 0 (0.0)
Prince Edward Island (1) 6 (6.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Newfoundland and Labrador (2) 5 (2.5) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Yukon (0) n/a n/a n/a n/a n/a n/a n/a n/a
Northwest Territories (2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Nunavut (2) 9 (4.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Canada (54) 753 (13.9) 214 (4.0) 10 (0.2) 81 (1.5) 6 (0.1) 28 (0.5) 2 (0.04) 7 (0.1)
  1. n/a not applicable